| P50 | author | Yuichiro Hatano | Q60965922 |
| | Hiroyuki Tomita | Q87735607 |
| | Akira Hara | Q88327545 |
| P2093 | author name string | Masayuki Niwa | |
| | Kei Noguchi | |
| | Tomohiro Kanayama | |
| | Ayumi Niwa | |
| | Mikiko Matsuo | |
| P2860 | cites work | Expression of galectin-3 modulates T-cell growth and apoptosis | Q24309392 |
| | Glial inhibition of CNS axon regeneration | Q24648851 |
| | Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis | Q24649584 |
| | N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin | Q24651908 |
| | The Role of Galectin-3 in the Kidneys | Q26752754 |
| | Galectin-Binding O-Glycosylations as Regulators of Malignancy | Q26801724 |
| | Galectin-3 in angiogenesis and metastasis. | Q27687444 |
| | Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis | Q28069174 |
| | Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells | Q28138960 |
| | Intracellular functions of galectins | Q28201120 |
| | Glycans, galectins, and HIV-1 infection | Q28265115 |
| | Galectins: structure, function and therapeutic potential | Q28283659 |
| | Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex | Q28577438 |
| | Galectin-3 mediates post-ischemic tissue remodeling | Q28578907 |
| | 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 |
| | Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets. | Q33608900 |
| | Diagnostic utility of galectin-3 in thyroid cancer. | Q33816239 |
| | Chronic upregulation of activated microglia immunoreactive for galectin-3/Mac-2 and nerve growth factor following diffuse axonal injury | Q33939361 |
| | Galectins distinctively regulate central monocyte and macrophage function | Q33949228 |
| | HFSA 2010 Comprehensive Heart Failure Practice Guideline | Q34124756 |
| | Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction | Q34364121 |
| | Galectin-3: an open-ended story | Q34494555 |
| | Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis | Q34501897 |
| | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut | Q34527664 |
| | Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction | Q34528187 |
| | 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society o | Q34556019 |
| | Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure | Q34566520 |
| | Identification of galectin-3 as a factor in pre-mRNA splicing | Q34706659 |
| | Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. | Q35109460 |
| | Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? | Q35286926 |
| | The nuclear IκB family protein IκBNS influences the susceptibility to experimental autoimmune encephalomyelitis in a murine model | Q35367737 |
| | Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. | Q48159180 |
| | Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives | Q48270428 |
| | Transport of fragmented DNA in apical dendrites of gerbil CA1 pyramidal neurons following transient forebrain ischemia | Q48394710 |
| | Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas | Q48731960 |
| | The fibrosis marker galectin-3 and outcome in the general population | Q48821773 |
| | Increase of galectin-3 expression in microglia by hyperthermia in delayed neuronal death of hippocampal CA1 following transient forebrain ischemia | Q48880930 |
| | Galectin-3 regulation of wound healing and fibrotic processes: insights for chronic skin wound therapeutics | Q49670112 |
| | The emerging role of galectins in high-fatality cancers | Q50101341 |
| | Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus | Q50126684 |
| | The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. | Q51273762 |
| | Galectin-3 is expressed in the myocardium very early post-myocardial infarction. | Q53651562 |
| | The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. | Q55023271 |
| | The Role of Galectins in Cervical Cancer Biology and Progression. | Q55152503 |
| | Galectins as Molecular Targets for Therapeutic Intervention. | Q55316400 |
| | Investigation of Gal-3 Expression Pattern in Serum and Cerebrospinal Fluid of Patients Suffering From Neurodegenerative Disorders | Q57000023 |
| | Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin | Q57395332 |
| | Galectin-3 predicts response and outcomes after cardiac resynchronization therapy | Q58614481 |
| | Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial | Q61716563 |
| | Time-course analysis of cardiac and serum galectin-3 in viral myocarditis after an encephalomyocarditis virus inoculation | Q61811369 |
| | Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients | Q64100032 |
| | The roles of galectin-3 and galectin-4 in the idiopatic Parkinson disease and its progression | Q64764673 |
| | Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. | Q64897354 |
| | Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family | Q73931768 |
| | National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure | Q80118278 |
| | Easing the brakes on spinal cord repair | Q80810720 |
| | Galectin-3 expression in delayed neuronal death of hippocampal CA1 following transient forebrain ischemia, and its inhibition by hypothermia | Q83285556 |
| | Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus | Q85759970 |
| | M1- and M2-macrophage polarization in rat liver cirrhosis induced by thioacetamide (TAA), focusing on Iba1 and galectin-3 | Q87712013 |
| | Galectin-3 is associated with left ventricular reverse remodeling and outcome after percutaneous mitral valve repair | Q88425185 |
| | Galectins at a glance | Q88537369 |
| | Galectin-3 in M2 Macrophages Plays a Protective Role in Resolution of Neuropathology in Brain Parasitic Infection by Regulating Neutrophil Turnover | Q89266985 |
| | The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature | Q90009237 |
| | Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction | Q90437159 |
| | Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes | Q90677157 |
| | Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure | Q90690500 |
| | Soluble ST2 and Galectin-3 and Progression of CKD | Q90819537 |
| | Exploring collagen remodeling and regulation as prognosis biomarkers in stable heart failure | Q91282523 |
| | Utility of Cardiac Biomarkers in the Setting of Kidney Disease | Q91380627 |
| | Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study | Q91895158 |
| | Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease | Q92377188 |
| | Biomarkers in heart failure: the past, current and future | Q92648647 |
| | Cardiac biomarkers in dialysis | Q92761146 |
| | Role and regulation mechanism of Gal-3 in non-small cell lung cancer and its potential clinical therapeutic significance | Q92953529 |
| | Galectin-3 may serve as a marker for poor prognosis in colorectal cancer: A meta-analysis | Q93043277 |
| | Galectin-3 is an independent predictor of survival in systemic sclerosis | Q39044041 |
| | Galectins: their network and roles in immunity/tumor growth control | Q39052321 |
| | Significance and Value of Endomyocardial Biopsy Based on Our Own Experience | Q39194453 |
| | Tumor-Associated Macrophages as Target for Antitumor Therapy. | Q39403895 |
| | Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker. | Q40451658 |
| | Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage | Q40616519 |
| | The change of plasma galectin-3 concentrations after traumatic brain injury | Q40871019 |
| | Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells | Q40933105 |
| | Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. | Q41322039 |
| | Early microlesion of viral encephalitis confirmed by galectin-3 expression after a virus inoculation | Q41452086 |
| | Expression of APC protein during tongue malignant transformation in galectin-3-deficient mice challenged by the carcinogen 4-nitroquniline-n-oxide | Q42735222 |
| | Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation | Q43411330 |
| | Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis | Q44361867 |
| | Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. | Q46067855 |
| | A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury | Q46461255 |
| | Galectin-3 in preneoplastic lesions of glioma. | Q46639546 |
| | Galectin-3 and Cancer Stemness. | Q47190193 |
| | Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. | Q47215149 |
| | Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). | Q47329197 |
| | Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis | Q47372910 |
| | Increased Plasma Galectin-3 Preceding the Development of Delayed Cerebral Infarction and Eventual Poor Outcome in Non-Severe Aneurysmal Subarachnoid Hemorrhage | Q47661952 |
| | Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity. | Q47679282 |
| | Galectin-3: an emerging biomarker in stroke and cerebrovascular diseases | Q47733264 |
| | Serum galectin-3 level in systemic sclerosis | Q47866004 |
| | Detection of galectin-3 and localization of advanced glycation end products (AGE) in human chronic skin wounds | Q47930144 |
| | Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. | Q47999828 |
| | Galectins: a family of animal beta-galactoside-binding lectins | Q48084852 |
| | Role of Galectins in Tumors and in Clinical Immunotherapy | Q48124343 |
| | Galectin-3, histone deacetylases, and Hedgehog signaling: Possible convergent targets in schistosomiasis-induced liver fibrosis | Q36288278 |
| | Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community | Q36439679 |
| | Microglia/macrophage-derived inflammatory mediators galectin-3 and quinolinic acid are elevated in cerebrospinal fluid from newborn infants after birth asphyxia | Q36937939 |
| | Prognostic value of plasma galectin-3 levels after aneurysmal subarachnoid hemorrhage | Q37339791 |
| | The immunological potential of galectin-1 and -3. | Q37343666 |
| | The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease | Q37404610 |
| | Viral causes of human myocarditis | Q37576182 |
| | Serial galectin-3 and future cardiovascular disease in the general population | Q37580709 |
| | Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. | Q37708778 |
| | A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus. | Q37742466 |
| | Early detection of myocardial dysfunction and heart failure | Q37748500 |
| | Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology | Q37847383 |
| | Galectin-3 and the skin | Q37926145 |
| | Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease | Q38055369 |
| | The pleiotropic effects of galectin-3 in neuroinflammation: a review | Q38073036 |
| | The use of biomarkers in the patient with heart failure | Q38104269 |
| | Galectin-3 in cancer. | Q38188296 |
| | Galectins as bacterial sensors in the host innate response | Q38192179 |
| | Extracellular galectin-3 in tumor progression and metastasis. | Q38225141 |
| | Galectins in tumor angiogenesis | Q38269050 |
| | Role of the interaction between galectin-3 and cell adhesion molecules in cancer metastasis | Q38347625 |
| | Galectin expression in cancer diagnosis and prognosis: A systematic review. | Q38394821 |
| | Galectin-3 and cardiac function in survivors of acute myocardial infarction. | Q38454450 |
| | Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis | Q38497448 |
| | The galectin lattice at a glance | Q38532853 |
| | Galectin-3 in autoimmunity and autoimmune diseases | Q38542678 |
| | Galectin 3 as a guardian of the tumor microenvironment | Q38564732 |
| | Role of galectin-3 in the pathogenesis of bladder transitional cell carcinoma | Q38597470 |
| | Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression | Q38742635 |
| | Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFβ1-induced macrophages | Q38758852 |
| | Galectin-3 in acute coronary syndrome | Q38812833 |
| | Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander | Q38831547 |
| | Galectin-3 expression in hippocampal CA2 following transient forebrain ischemia and its inhibition by hypothermia or antiapoptotic agents. | Q38843390 |
| | Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression | Q38930686 |
| | Role of galectin-3 in autoimmune and non-autoimmune nephropathies | Q38964155 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P433 | issue | 3 | |
| P921 | main subject | heart disease | Q190805 |
| | biomarker | Q864574 |
| P577 | publication date | 2020-03-03 | |
| P1433 | published in | Biomolecules | Q23929963 |
| P1476 | title | Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases | |
| P478 | volume | 10 | |